Ian Murray

We do not disagree with the principle of Herbie’s law; indeed, that is what the strategy is trying to achieve. The challenge for the Government, of course, is to balance that against what is achievable and what can be validated, not just in the UK but across the international community. We want this country to be a world leader in eliminating animal research, and it is pretty clear, on the front page of the strategy, that we wish to take those 26 actions on. Let me continue as that will help to answer the hon. Member’s question. The hon. Member for Yeovil (Adam Dance) challenged us to say what the strategy has delivered so far. We have moved from commitments towards trying to deliver. With the actions under way across discovery, research, validation, regulatory decision making and governance, and indeed the money to support some of that, delivery is being supported through co-ordinated action across the Office for Life Sciences, NC3Rs, UKRI bodies and regulators. The MRC has launched the £20 million fund to which I referred, and Innovate UK and NC3Rs continue to work in partnership to advance development. In March 2026, the MHRA published new guidance setting out how applications for medicines that use non-animal methods will be assessed and fast-tracked. A lot of the strategy has therefore already been put in place, but the strategy cannot be just words; it needs action as well. Let me run through some of the challenges and questions raised by hon. Members in what has been a tremendously good debate for examining the issues. My hon. Friend the Member for North Ayrshire and Arran chairs the relevant all-party parliamentary group, the aims of which are: “To build cross-party support for replacing animal experiments in medical research with human-specific methods, working closely with the scientific community to identify opportunities, barriers and put forward constructive recommendations to government.” Those are almost the same aims as what the Government are trying to achieve through the strategy. We and the APPG are aligned in the outcome we want. We look forward to continuing to work with her and the other APPG members to get it delivered. I want to say something for clarity, because my hon. Friend raised this in some of what she said—we heard it from many hon. Members—and there has been a little confusion not just in this debate, but in previous debates. The testing of cosmetics was banned in 1998 and the testing of household products was banned in 2015. Progress has been slower than we would have wanted, but we hope that the new strategy will speed things up and give certainty to industry. My hon. Friend the Member for North Ayrshire and Arran mentioned botox, as did the hon. Member for Huntingdon and, in an intervention, the hon. Member for Bromsgrove (Bradley Thomas). Botox is not a cosmetic, so it is not covered by existing regulations on cosmetics, as we heard, but the strategy sets an aim to apply only validated alternative methods for testing the potency of botox by the end of 2027. The MHRA now accepts an alternative for most common strengths of botox, so we hope to see the practice phased out within the next 18 months or so. The hon. Member for Huntingdon gave us a whole list of questions, some of which are the responsibility of the Home Office, so if I do not cover them all, I will ensure that he gets a detailed analysis from that Department. We will provide an update later this year about the international perspectives, because at the moment we are working out and scoping what those perspectives look like. He asked about funding. Out of the £75 million, £20 million is for the translational hub and £30 million is for the UK centre for the validation of alternative methods. It does not cover NC3R’s funding. Tomorrow, we are discussing KPIs at an official level—the hon. Gentleman challenged us about what tomorrow’s meeting will do. The matter will then go to a ministerial meeting, which happens every quarter, with the next one due on 8 July. He also talked about criminalisation. I will get the Home Office to detail a response to him in writing, but while the law criminalises interfering or planning to interfere with key national infrastructure, it does not cover the email situation he talked about. My hon. Friend the Member for Bristol East (Kerry McCarthy) asked if any consideration was given to the reviewing, reworking and revoking of licences. Again, that is a Home Office responsibility, so I will get a full response about how it monitors licences. She also challenged us on the use of AI, and we need to look at that. Many advances in medical research are happening with AI enhancement at the moment, including on motor neurone disease and how the brain operates, as I know from my constituency. AI and advances in technology will be a key part of how we phase out the use of animal testing. The hon. Member for Taunton and Wellington (Gideon Amos) asked if the regulatory body should be paid for by the industry, but that is not the case. The regulatory body charges for its licensing; it is not paid for directly. That does not amount to the industry funding the regulator. It is standard practice for people to buy the regulatory services that are required. My hon. Friend the Member for City of Durham (Mary Kelly Foy) challenged us to say more than warm words. That is what I think the strategy is about and why we are advancing it rather quickly. The dates by which we need to achieve many of the issues are in the strategy. I thank the hon. Member for Waveney Valley (Adrian Ramsay) for his comments. I appreciate the fact that he welcomes the strategy, although I know he wants us to go quicker, faster and with more pace, as many Members have said. He raised the issue of Herbie’s law by 2035, but we have to ensure that replacements put in place for that to happen in an orderly fashion. My hon. Friend the Member for Doncaster East and the Isle of Axholme (Lee Pitcher) asked us for a fourth R—“replace”. That is what investment in the strategy is all about, and it is why the money is available. The hon. Member for Didcot and Wantage (Olly Glover) talks to his cats—interesting—although I do not know whether he ever gets a response. I hope he is not opening up a debate in Westminster Hall about whether someone is a dog person or a cat person, because that could take us to—I am extending the pun even further—a rabbit hole that we might not want to go down. My hon. Friend the Member for Paisley and Renfrewshire South (Johanna Baxter) certainly is a cat lover. I believe she has a cat called Clement Catlee, and another called Chairman Meow—is that right?